Login to Your Account



Clinic Roundup


Thursday, September 20, 2012
• Aerpio Therapeutics Inc., of Cincinnati, said it dosed the first patient in a Phase Ib/IIa trial of AKB-9778, a human protein tyrosine phosphate beta inhibitor designed to activate Tie2, for diabetic macular edema.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription